Literature DB >> 33341181

Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.

M Eugenia Socías1, Huiru Dong2, Evan Wood1, Seonaid Nolan1, Kanna Hayashi3, Thomas Kerr1, M-J Milloy4.   

Abstract

INTRODUCTION: Retention in opioid agonist therapy consistently has been linked with improved outcomes among people with opioid use disorder. However, less is known about the links between patterns of engagement in opioid agonist therapy over the long term and overdose risk. This study assesses the association of opioid agonist therapy retention trajectories with nonfatal overdose.
METHODS: Data were drawn from 2 community-recruited prospective cohorts of people who use drugs in Vancouver, Canada. Latent class growth analysis was used to identify trajectories of opioid agonist therapy retention among people with opioid use disorder initiating therapy, and generalized estimating equations assessed the association of these trajectories with nonfatal overdose events after opioid agonist therapy initiation.
RESULTS: Between 2005 and 2018, among 438 opioid agonist therapy initiators, 4 retention trajectories were identified: consistently high (35.6%), increasing (26.0%), consistently low (23.3%), and decreasing (15.1%) opioid agonist therapy engagement. During the study period, there were 371 nonfatal overdose events, with 179 (40.1%) participants reporting ≥1. In adjusted analysis, the consistently low (AOR=1.73, 95% CI=1.10, 2.71) and decreasing (AOR=1.87, 95% CI=1.18, 2.95) retention trajectories were positively associated with increased odds of nonfatal overdose compared with the consistently high opioid agonist therapy retention class.
CONCLUSIONS: Suboptimal trajectories of opioid agonist therapy retention were associated with an increased likelihood of nonfatal overdose. These findings suggest that reducing the barriers to sustained engagement in opioid agonist therapy will be critical to address North America's overdose epidemic.
Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33341181      PMCID: PMC7978040          DOI: 10.1016/j.amepre.2020.07.006

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  22 in total

1.  Addiction treatment-related employment barriers: the impact of methadone maintenance.

Authors:  Lindsey Richardson; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Housing instability and food insecurity as barriers to health care among low-income Americans.

Authors:  Margot B Kushel; Reena Gupta; Lauren Gee; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2006-01       Impact factor: 5.128

3.  Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population.

Authors:  J De Irala; C Bigelow; J McCusker; R Hindin; L Zheng
Journal:  Am J Epidemiol       Date:  1996-04-01       Impact factor: 4.897

Review 4.  Management of opioid use disorder in the USA: present status and future directions.

Authors:  Carlos Blanco; Nora D Volkow
Journal:  Lancet       Date:  2019-03-14       Impact factor: 79.321

Review 5.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

6.  Trajectories of retention in opioid agonist therapy in a Canadian setting.

Authors:  M Eugenia Socías; Huiru Dong; Evan Wood; Rupinder Brar; Lindsey Richardson; Kanna Hayashi; Thomas Kerr; M-J Milloy
Journal:  Int J Drug Policy       Date:  2020-02-09

7.  Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.

Authors:  M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

8.  Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes.

Authors:  B Muthén; L K Muthén
Journal:  Alcohol Clin Exp Res       Date:  2000-06       Impact factor: 3.455

9.  Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data.

Authors:  Mark A Stoové; Paul M Dietze; Damien Jolley
Journal:  Drug Alcohol Rev       Date:  2009-07

10.  Barriers to use of free antiretroviral therapy in injection drug users.

Authors:  S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

View more
  1 in total

1.  Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids.

Authors:  Stephen Juwono; M-J Milloy; JinCheol Choi; Nadia Fairbairn; Seonaid Nolan; M Eugenia Socías
Journal:  AIDS       Date:  2022-05-25       Impact factor: 4.632

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.